Lazard Asset Management
VKTX icon

Lazard Asset Management’s Viking Therapeutics VKTX Stock Holding History

Lazard Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,801
Closed -$207K – 2488
2023
Q2 		$207K Buy
+12,801
New +$268K ﹤0.01% 1335

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Lazard Asset Management's VKTX Position: Q3 2023 in Review

Lazard Asset Management sold out of Viking Therapeutics (VKTX) in Q3 2023, closing a stake of 12,801 shares — an estimated $207K sold.

Lazard Asset Management first reported a position in VKTX in Q2 2023 and held it in 1 quarter. The position peaked at $207K in Q2 2023. 179 funds tracked by Wall St. Rank hold VKTX as of Q3 2023.

  • Lazard Asset Management reported no remaining Viking Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lazard Asset Management sold 12,801 Viking Therapeutics shares in Q3 2023, an estimated $207K.
  • Lazard Asset Management first reported a position in Viking Therapeutics in Q2 2023 and held it in 1 quarter.
  • Lazard Asset Management's Viking Therapeutics position peaked at $207K in Q2 2023.
  • 179 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2023.

Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.